Nipah pseudovirus system enables evaluation of vaccines in vitro and in vivo using non-BSL-4 facilities.

ABSTRACT: Because of its high infectivity in humans and the lack of effective vaccines, Nipah virus is classified as a category C agent and handling has to be performed under biosafety level 4 conditions in non-endemic countries, which has hindered the development of vaccines. Based on a highly efficient pseudovirus production system using a modified HIV backbone vector, a pseudovirus-based mouse model has been developed for evaluating the efficacy of Nipah vaccines in biosafety level 2 facilities. For the first time, the correlates of protection have been identified in a mouse model. The limited levels of neutralizing antibodies against immunogens fusion protein (F), glycoprotein (G), and combination of F and G (FG) were found to be 148, 275, and 115, respectively, in passive immunization. Relative

SUBMITTER: Nie J 

PROVIDER: S-EPMC6455126 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature